Biosimilars In EU: From 'New Mess' To Beacon For Safety

Finnish Medicines Agency's Ekman says neither regulators nor industry knew what to do when the biosimilars regulatory framework was first introduced, but there haven't been any differences in adverse events between biosimilars and their reference products.

airport runway under the sun as background

When the biosimilar regulatory framework was first introduced in the European Union (EU) in 2004, the whole thing was a "new mess," says Finnish Medicines Agency senior researcher Niklas Ekman.

"Industry didn't know how to do things," Ekman said June 26 at the 2017 Parental Drug Association/US FDA Biosimilars Conference....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics